Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Patricia Lee

Dermatology Webster, TX Medical Doctor

NPI 1831335918 CMS profile 264427

451 N Texas Ave, Webster, TX 77598

Open in the dashboard

General payments

$36,599

617 records reported · program years 2019–2025

Research payments

$38,437

Paid to them · 27 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$7,180,884 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Patricia Lee of Webster, TX is reported in the CMS Open Payments database as having received $36,599 across 617 general payments and $38,437 in research payments paid to them. Separately, studies naming them as principal investigator received $7,180,884 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 94th percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

14 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $7,278 125
2025 Research $1,472 7
2024 General $5,128 109
2024 Research $7,539 6
2023 General $7,171 128
2023 Research $10,166 5
2022 General $4,565 97
2022 Research $215 1
2021 General $3,905 73
2021 Research $3,287 2
2020 General $897 27
2020 Research $6,033 4
2019 General $7,656 58
2019 Research $9,724 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Patricia Lee
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Patricia Lee were reported at $7,278. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Patricia Lee Dermatology median Middle half National median
2019 $7,656 $454 $129–$1,240 $163
2020 $897 $235 $81–$756 $114
2021 $3,905 $377 $108–$1,108 $132
2022 $4,565 $514 $143–$1,391 $149
2023 $7,171 $607 $159–$1,674 $160
2024 $5,128 $751 $204–$1,903 $164
2025 $7,278 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $6,876 153 payments
  2. Pfizer Inc. $3,795 23 payments
  3. E.R. Squibb & Sons, L.L.C. $2,628 25 payments
  4. Boehringer Ingelheim International GmbH $2,552 3 payments
  5. Sun Pharmaceutical Industries Inc. $2,540 65 payments
  6. Janssen Biotech, Inc. $2,004 75 payments
  7. Janssen Scientific Affairs, LLC $1,858 16 payments
  8. Novartis Pharmaceuticals Corporation $1,856 11 payments
  9. Genzyme Corporation $1,445 42 payments
  10. Regeneron Healthcare Solutions, Inc. $1,153 27 payments
  11. Other $9,893 177 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $29,019 598 payments
  2. Travel and Lodging $3,351 13 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $2,552 3 payments
  4. Consulting Fee $1,500 1 payment
  5. Education $177 2 payments
Products named General payments · program years 2019–2025
  1. TREMFYA $3,777 88 payments
  2. SKYRIZI $3,326 78 payments
  3. RINVOQ $3,090 62 payments
  4. ILUMYA $1,761 40 payments
  5. DUPIXENT Immunology $1,150 47 payments
  6. Winlevi $982 22 payments
  7. Otezla $772 18 payments
  8. SOTYKTU $765 20 payments
  9. DUPIXENT Inflammation And Immunology $732 17 payments
  10. Absorica LD $729 22 payments
  11. Other $10,700 226 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Sanofi US Services Inc. $17,705 11 payments
  2. Eli Lilly and Company $14,202 4 payments
  3. Almirall LLC $3,287 2 payments
  4. Novartis Pharmaceuticals Corporation $1,770 3 payments
  5. Regeneron Pharmaceuticals, Inc. $1,472 7 payments

Records

644 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record